The Biochemical Bone Marker Market - Dawn or Dusk?
This article was originally published in Clinica
Biochemical bone marker tests, especially those for bone resorption, are on the brink of being established as a routine tool in the management of osteoporosis. Until two years ago, the new market of resorption tests was one of the fastest growing sectors in immunodiagnostics. Nonetheless, the share prices of the two main players - Metra Biosystems and Ostex International - have reached an all-time low of below $1.00.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.